Biotechnology

MABWELL-B

Mwim Biotech's Denosumab Injection Approved for New Indications Including Bone Metastasis

Mabwell Biologics Receives FDA Approval for 9MW5211 Clinical Trials

Mabwell Biologics' 9MW5211 Clinical Trial Application Approved by FDA

Mabwell Biopharma-B Plans to Apply for Registration of Up to 1 Billion Yuan Directed Debt Financing Instruments

MaiWei Biopharma Discloses Latest Clinical Trial Results for Novel ADC for Cervical Cancer Treatment

MABWELL-B released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue HKD 144.66 M, actual EPS HKD -0.6915

Mabwell Biologics Submits IND for Global First-in-Class LILRB4/CD3 TCE Bispecific Antibody 6MW5311

MABWELL-B to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

MABWELL-B released FY2024 Q4 earnings on March 24 Post-Market (BJT), actual revenue HKD 62.43 M, actual EPS HKD -0.9231

MABWELL-B released FY2025 Annual Earnings on March 24 (BJT), actual revenue HKD 724.1 M (forecast HKD 788.99 M), actual EPS HKD -2.6558

MABWELL-B released FY2025 Q4 earnings on March 24 (BJT), actual revenue HKD 107.51 M, actual EPS HKD -1.0325

MABWELL-B released FY2024 Annual Earnings on March 24 (BJT), actual revenue HKD 216.26 M (forecast HKD 364.19 M), actual EPS HKD -2.8252

MABWELL-B released FY2025 Q3 earnings on October 30, 2025 (BJT), actual revenue HKD 507.96 M, actual EPS HKD -0.1278

MABWELL-B released FY2024 Q3 earnings on October 30, 2025 (BJT), actual revenue HKD 28.34 M, actual EPS HKD -0.6991

MABWELL-B released FY2024 9 Months earnings on October 30, 2025 (BJT), actual revenue HKD 153.1 M, actual EPS HKD -1.8971

MABWELL-B released FY2025 9 Months Earnings on October 30, 2025 (BJT), with actual revenue of HKD 617.64 M and actual EPS of HKD -1.621

MABWELL-B released FY2024 semi-annual earnings on August 29 (BJT), actual revenue HKD 124.67 M, actual EPS HKD -1.1978

2493.HK released FY2025 Semi-Annual Earnings on August 29 (BJT), actual revenue HKD 109.54 M, actual EPS HKD -1.4941

MABWELL-B released FY2024 Q2 earnings on August 29, 2025 (BJT), actual revenue HKD 51.55 M, actual EPS HKD -0.6452

MABWELL-B released FY2025 Q2 earnings on August 29 (BJT), actual revenue HKD 61.71 M, actual EPS HKD -0.7114

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02493

688062

Mabwell has received FDA clearance for its IND application for 9MW5211, a novel antibody aimed at treating inflammatory bowel disease (IBD). This marks the world's first clinical-stage drug candidate targeting this condition. The antibody selectively depletes pathogenic immune cells, potentially improving patient outcomes. Clinical trial applications for multiple indications, including IBD and multiple sclerosis, are under review in China. Preclinical studies indicate significant therapeutic potential, and safety evaluations show a favorable profile. Mabwell aims to enhance treatment accessibility and effectiveness in autoimmune diseases.

prnewswire

Mabwell

20:00 ETWorld's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

Mabwell (Shanghai) Bioscience Co., Ltd. has received FDA clearance for a first-in-human trial of its antibody candidate 9MW5211, aimed at treating inflammatory bowel disease. The trial will assess safety and tolerability in healthy subjects. The drug targets pathogenic immune cells and has shown promising preclinical results. Mabwell is expanding its global presence in autoimmune therapies, despite the uncertainties of drug development. The success of 9MW5211 could lead to significant market opportunities and improved patient outcomes, although future approvals depend on trial results and regulatory decisions.

Tip Ranks

Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211

Mabwell (Shanghai) Bioscience Co., Ltd. has announced a shift to electronic corporate communications for non-registered shareholders, complying with Hong Kong Listing Rules. Future reports and documents will be available in English and Chinese on the company's website and the Hong Kong Stock Exchange platform, eliminating individual notifications. Shareholders preferring hard copies can request them, but requests will only be valid until the end of the next financial year. This move emphasizes a transition towards digital communications in the biopharmaceutical sector.

Mabwell Moves Non-Registered Shareholders to Digital Corporate Communications

Mabwell (Shanghai) Bioscience Co., Ltd. plans to issue targeted debt financing instruments of up to RMB 1 billion to optimize its capital structure. The bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors. Proceeds will be used for repaying liabilities, funding project construction, and replenishing working capital. The board has approved the proposal, pending shareholder approval and regulatory clearance. Mabwell focuses on developing innovative biologic therapies and is listed in Hong Kong.

Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure

MABWELL-B (2493.HK) is currently priced at HK$27.100, down -0.51% for the day, with a 5-minute intraday increase of over 3%, and a market capitalization of HKD 12.3 billion. The company focuses on the research and development of innovative drugs, with short-term capital driving the stock price up during the trading session. There have been no major announcements recently, and the fluctuations may be related to active trading and market interest in the innovative pipeline

Movers Alert

Maiwei Bio (2493.HK) Spikes on Short-Term Rally

MABWELL-B (2493.HK) current price is 26.840, up 5.34% for the day, with an intraday increase exceeding 5%, and a market capitalization of 12 billion. The company focuses on the research and development of innovative drugs, and its first-day closing performance was outstanding. Recently, it will showcase cervical cancer clinical data at ESMO GC, with the new pipeline becoming a market focus. There are no other significant catalysts at the moment, and stock price fluctuations may be influenced by capital demand

MW Bio-B (2493.HK) surged over 5% intraday

01921

02650

03347

02583

01528

02685

02635

01879

00068

DALIPAL HLDG(01921) fell 17.55%, with a trading turnover 48.2 Million HKD, and a year-to-date fell 39.9%. ZHIDA TECH(02650) fell 11.12%, with a trading turnover 114.2 Million HKD, and a year-to-date fell 37.1%. TIGERMED(03347) fell 10.05%, with a trading turnover 201.9 Million HKD, and a year-to-date fell 7%.

Top Gainers&Losers

DALIPAL HLDG

ZHIDA TECH

TIGERMED

HIPINE

RS MACALLINE

QUANTGROUP

NUOBIKAN

XIZHI TECH-P

MANYCORE TECH

Top 10 HK Stock Losers (4.29)

Mabwell (Shanghai) Bioscience Co., Ltd. has officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX) as of April 28, 2026. The company, founded in 2017, specializes in innovative pharmaceuticals with a focus on oncology, immunology, and other therapeutic areas. Mabwell boasts a diverse product pipeline, including 4 commercialized products and 10 drug candidates, with significant advancements in antibody-drug conjugates (ADCs). The company has also expanded its global market presence through strategic partnerships and commercialization efforts in various countries.

Asian Corporate Newswire

Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX

MABWELL-B(02493.HK)